MIA Antibody

1. the molecular basis of the interaction of MIA with the Hep II domain of fibronectin based on nuclear magnetic resonance spectroscopic binding assays. PMID:28565914
2. The frequency of MIA gene family expression was higher among squamous cell carcinomas than among other tumor types subjected to screening. MIA gene family staining was observed frequently in esophageal and lung cancers associated with nodal and/or distant metastasis. In cervical cancers, MIA and TANGO immunostaining also correlated with tumor progression and metastasis. PMID:27145272
3. Our results suggest that MIA-STOX2 signaling may be a useful diagnostic and therapeutic target in oral squamous cell carcinoma PMID:27050375
4. MIA had a slightly superior sensitivity to detect progressive disease compared to S100 and seems to be more useful in monitoring of patients with metastatic melanoma receiving immunotherapy PMID:28870930
5. real-time RT-PCR assays showed that expressions of MIA and MIA-RAB4B located 35 kb upstream of the deletion, were up-regulated in the polyps compared to the matched mucosa of the proband. MIA-RAB4B, the read-through long non-coding RNA (lncRNA), RAB4B, PIM2 and TAOK1 share common binding site of a microRNA, miR-24, in their 3'UTRs PMID:28306719
6. The effects of MIA/CD-RAP on transcriptional regulation in chondrocytes, through the regulation of p54(nrb) via YBX1 contributes to the understanding of chondrogenesis. PMID:24349210
7. data provide evidence for a critical role of SOX10 in melanoma cell invasion through the regulation of MIA and highlight its role as a therapeutic target in melanoma PMID:24608986
8. Focus on the quantitative analysis of the MIA protein as a prognostic tool because it has proven to be a useful serum marker for documenting disease progression of malignant melanoma. Review. PMID:24372647
9. Functional promoter analysis identified the transcription factor YBX1 as the mediator of MIA activation of p54(nrb) transcription. PMID:23672612
10. MIA protein is present in non-segmental vitiligo skin and may cause the detachment of melanocytes; its target is integrin alpha5beta1, which determines the breaking and/or weakening of connections among melanocytes and basal membrane PMID:23664187
11. Results show that S-100B, MIA and LDH levels were significantly higher in patients with advanced melanoma than in disease-free patients or healthy controls. PMID:21858537
12. assessed the utility of melanoma inhibitory activity (MIA) serum marker in the follow up and primary diagnosis of stage III melanoma patients PMID:21658116
13. Further diagnostics should be initiated in uveal melanoma patients with serum MIA above 8.3ng/ml. PMID:21540751
14. Data suggest that plasma markers: CEACAM, ICAM-1, osteopontin, MIA, TIMP-1 and S100B particularly when assessed in combination, can be used to monitor patients for disease recurrenc. PMID:21487066
15. The cell-specific production rate of MIA was quantitatively proportional to the aggrecan gene expression level in the early and middle phase of cartilage chondrocyte differentiation. PMID:21277254
16. MIA/CD-RAP stabilizes cartilage differentiation and inhibits differentiation into bone potentially by regulating signaling processes during differentiation. PMID:20164682
17. pancreatic cancer patients with high intratumoral expression are antibody-negative and have shorter survival PMID:20514540
18. A fluorescence polarization biological assay was developed using MIA protein-binding compounds for studies of the binding properties of this protein. PMID:19852767
19. The assignments, solution structure, & dynamics of human MIA were determined by heteronuclear NMR methods. The structure consists of an SH3-like subdomain with N- and C-terminal extensions of about 20 amino acids each that form a novel fold. PMID:11991352
20. Melanoma-inhibiting activity (MIA/CD-RAP) is expressed in a variety of malignant tumors of mainly neuroectodermal origin. PMID:12014625
21. expression pattern of a novel splice product MIA (splice) of malignant melanoma-derived growth-inhibiting activity (MIAY CD-RAP). PMID:12230496
22. Stable antisense-HMG1 expression in melanoma cells led to the reduction of melanoma inhibitory activity (MIA) promoter activity and protein expression. PMID:12665595
23. increased MIA production may, in turn, increase the invasive properties of the cells by modulating the attachment of human uveal melanoma cells to the extracellular matrix PMID:15057037
24. MIA may promote the detachment of radial and vertical growth phase melanomas. PMID:15201995
25. The MIA protein enhances the migration of melanocytes and promotes melanoma progression. PMID:15208686
26. MIA may contribute to immunosuppression frequently seen in malignant melanomas by inhibiting cellular antitumor immune reactions. PMID:15386421
27. MIA in homogenates of surgical specimen directly relate to a more benign clinical prognosis in patients with high-grade glioma PMID:15547763
28. There is a correlation between MIA expression and pigmentation and morphology of melanocytic cells. PMID:15760338
29. Increased levels of MIA is associated with gastric cancer PMID:16331256
30. When patients progressed, level of MIA increased significantly. PMID:17348447
31. A candidate autoantigen in rheumatoid arthritis found in synovial fluid cells. PMID:17599744
32. An antigen in melanoma, elevated in 22 per cent of patients, predicting recurrence. PMID:17661202
33. MIA serum level is the ideal test for screening the skin melanoma spread to sentinel lymph nodes. PMID:18477894
34. MIA expression is enhanced by the interaction of intracellular HMGB1 and NFkBp65 and MIA is closely involved in tumor progression and nodal metastasis by the increments of VEGF-C and VEGF-D in oral squamous cell carcinomas. PMID:18616526
35. MIA protein, binding to integrins and thus promoting detachment of cells from extracellular matrix structures, is internalized into the cell together with these cell adhesion receptors at the cell rear. PMID:19521988

Show More

Hide All

HGNC: 7076

UNIGENE: Hs.646364

KEGG: hsa:8190

STRING: 9606.ENSP00000263369

OMIM: 601340